Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trovafloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 1/20 | 1.00 |
| ▸ | FLT4 | P35916 | 1/20 | 1.00 |
| ▸ | GSK3B | P49841 | 1/20 | 1.00 |
| ▸ | RARB | P10826 | 1/20 | 1.00 |
| ▸ | TBXAS1 | P24557 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 0.90 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.90 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.90 |
| ▸ | HPGD | P15428 | 2/20 | 0.90 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.90 |
| ▸ | POLB | P06746 | 2/20 | 0.90 |
| ▸ | XBP1 | P17861 | 1/20 | 0.90 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.90 |
| ▸ | HTT | P42858 | 1/20 | 0.90 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.90 |
| ▸ | RELA | Q04206 | 1/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
| ▸ | DPP4 | P27487 | 6/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trovafloxacin SCHEMBL1902266 | 1.00 | EPHA2 (1.00) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL20769811 | 1.00 | EPHA2 (1.00) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL13575805 | 1.00 | EPHA2 (1.00) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL34466 | 1.00 | EPHA2 (1.00) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL29384064 | 1.00 | EPHA2 (1.00) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL29688441 | 1.00 | EPHA2 (1.00) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL9177464 | 1.00 | EPHA2 (1.00) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL29711175 | 0.99 | EPHA2 (0.98) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL1229029 | 0.99 | EPHA2 (0.98) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL7688504 | 0.99 | EPHA2 (0.98) | EPHA2FLT4GSK3BRARBTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 18968 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624057-B2 | Bisphosphonate quinolone conjugates and uses thereof | BIOVINC, LLC (US) | 2026-05-12 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| EP-4434588-B1 | AEROSOL DELIVERY DEVICE | PARI PHARMA GMBH (DE) | 2026-04-08 | — | — | EP | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| US-20260027140-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | ATOPIC MEDICAL INC (US) | 2026-01-29 | — | — | US | claimed |
| EP-4659014-A1 | EMULSION-BASED THICK-FILM ANTIFOULING COATING FOR HIGHLY SENSITIVE ELECTROCHEMICAL SENSING | President And Fellows Of Harvard College (US) | 2025-12-10 | — | — | EP | claimed |
| US-12465623-B2 | Use of parasites and extracellular vesicles obtained from parasites in cancer treatment | YEDITEPE UNIVERSITESI (TR) | 2025-11-11 | — | — | US | claimed |
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2025-11-06 | — | — | US | claimed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| WO-1999000136-A1 | CONTROL OF ACIDIC GUT SYNDROME | THE UNIVERSITY OF NEW ENGLAND (AU) | 1999-01-07 | — | — | WO | claimed |
| CN-1193977-A | Polymorphs of the prodrug 6-N- (L-alanine-L-alanine) -trovafloxacin | PFIZER (US) | 1998-09-23 | — | — | CN | claimed |
| WO-1998036732-A2 | COMBINATION PREPARATION FOR ORALLY ADMINISTERED ANTIBIOTICS | LINDOPHARM GMBH (DE) | 1998-08-27 | — | — | WO | claimed |
| CN-1190889-A | Zwitterionic forms of trovafloxacin | PFIZER (US) | 1998-08-19 | — | — | CN | claimed |
| EP-0850060-A1 | ZWITTERIONIC FORMS OF TROVAFLOXACIN | PFIZER INC. (US) | 1998-07-01 | — | — | EP | claimed |
| EP-0789697-B1 | CRYSTAL FORM OF ANHYDROUS 7-((1a,5a, 6a)-6-AMINO-3-AZABICYCLO ( 3.1. 0]HEX-3-YL)-6-FLUORO-1-(2,4-DIFLUOROPHENYL)-1,4-DIHYDRO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID, METHANESULFONIC ACID SALT | PFIZER (US) | 1998-06-17 | — | — | EP | claimed |
| WO-1997008191-A1 | POLYMORPHS OF THE PRODRUG 6-N-(L-ALA-L-ALA)-TROVAFLOXACIN | PFIZER INC. (US) | 1997-03-06 | — | — | WO | claimed |
| WO-1997007800-A1 | ZWITTERIONIC FORMS OF TROVAFLOXACIN | PFIZER INC. (US) | 1997-03-06 | — | — | WO | claimed |
| US-5164402-A | Bactericides | PFIZER INC (US) | 1992-11-17 | — | — | US | claimed |
| WO-1991002526-A1 | AZABICYCLO QUINOLONE CARBOXYLIC ACIDS | PFIZER INC. (US) | 1991-03-07 | — | — | WO | claimed |